Beigene’s Zanubrutinib (BGB-3111) Receives the US FDA’s Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)

 Beigene’s Zanubrutinib (BGB-3111) Receives the US FDA’s Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)

Beigene’s Zanubrutinib (BGB-3111) Receives the US FDA’s Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)

Shots:
  • The BT designation follows the P-II trial assessing Zanubrutinib in patients with 1L mantle cell lymphoma
  • Beigene’s Zanubrutinib is being evaluated globally in seven P-III trials in multiple areas including one for patients with waldenstrom macroglobulinemia (WM) with zanubrutinib vs ibrutinib and P-II for r/r follicular lymphoma in combination with Gazyva (obinutuzumab)
  • Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase (BTK) inhibitor and has also received NMPA’s (CMPA) priority review for r/r MCL and r/ r CLL/SLL in China

Click here to read full press release/ article | Ref: Globe News Wire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post